Immunology letters最新文献

{"title":"In vitro antibody-mediated SARS-CoV-2 infection suppression through human ACE2 receptor blockade","authors":"Priscilla S. Redd ,&nbsp;Alyssa D. Merting ,&nbsp;John D. Klement ,&nbsp;Dakota B. Poschel ,&nbsp;Dafeng Yang ,&nbsp;Kebin Liu","doi":"10.1016/j.imlet.2024.106887","DOIUrl":"10.1016/j.imlet.2024.106887","url":null,"abstract":"<div><p>Vaccines and antibodies that specifically target or neutralize components of the SARS-CoV-2 virus are effective in prevention and treatment of human patients with SARS-CoV-2 infection. However, vaccines and SARS-CoV-2 neutralization antibodies target a subset of epitopes of viral proteins, and the fast evolution of the SARS-CoV-2 virus and the continuing emergence of SARS-CoV-2 variants confer SARS-CoV-2 immune escape from these therapies. ACE2 is the human cell receptor that serves as the entry point for SARS-CoV-2 into human cells and thus is the gatekeeper for SARS-CoV-2 infection of humans. We report here the development of 4G8C11, an anti-human ACE2 receptor monoclonal antibody that recognizes ACE2 on human cell surfaces. We determined that 4G8C11 blocks SARS-CoV-2 and variant infection of ACE2⁺ human cells. Furthermore, 4G8C11 has minimal effects on ACE2 receptor activity. 4G8C11 is therefore a monoclonal antibody for ACE2 receptor detection and potentially an effective immunotherapeutic agent for SARS-CoV-2 and variants.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106887"},"PeriodicalIF":3.3,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated Th17/Treg cell axis is correlated with local and systemic immune response in human intermediate uveitis","authors":"Chaman Saini ,&nbsp;Leena Sapra ,&nbsp;Prabhav Puri ,&nbsp;Pradyumna K. Mishra ,&nbsp;Rohan Chawla ,&nbsp;Rupesh K. Srivastava","doi":"10.1016/j.imlet.2024.106888","DOIUrl":"10.1016/j.imlet.2024.106888","url":null,"abstract":"<div><p>Th17/Treg cell balance is essential for immune homeostasis and when disrupted, is associated with the occurrence and development of inflammation in numerous autoimmune diseases. However, its contribution in pathophysiology of uveitis remains unexplored. In this study, we deciphered the role of Th17/Treg cell balance in autoimmune uveitis subjects. Using flow cytometry, we detected the frequencies and absolute count of both Th17 and Treg cells in the aqueous humor and peripheral blood of patients and healthy controls. Our results for the first time reveal a significant increase (<em>p</em> &lt; 0.01 and <em>p</em> &lt; 0.005) in Th17 population alongside a significant decrease (<em>p</em> &lt; 0.001 and <em>p</em> &lt; 0.003) in Treg cell population in both the aqueous humor and PBMCs of uveitis patients. Further we analyzed the expression of Th17-Treg associated genes and cytokines via qPCR and ELISA respectively. These findings align with our flow cytometry results, as evident by a significant (<em>p</em> &lt; 0.002) up-regulation of <em>IL-17</em> and a concurrent down regulation of <em>IL-10</em> at transcriptional levels. Moreover, IL-17A cytokine was found to be substantially high (<em>p</em> &lt; 0.001) and IL-10 (<em>p</em> &lt; 0.02) down regulated in serum. Interestingly, we demonstrated a significant correlation of Th17/Treg cells in aqueous humor with those in peripheral blood. Conclusively, our results suggest the pivotal role of Th17/Treg cell axis in the immuno-pathophysiology of human uveitis. Further we propose the therapeutic potential of targeting this novel axis for ameliorating the disease burden associated with uveitis.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106888"},"PeriodicalIF":3.3,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced EO771-induced tumour growth and increased overall-survival of mice ablated for immune cell-specific catalytic subunit Cβ2 of protein kinase A","authors":"Shuai Guo ,&nbsp;Shrikant Kolan ,&nbsp;Gaoyang Li ,&nbsp;Clara Louise Hammarström ,&nbsp;Franco Grimolizzi ,&nbsp;Linda Elin Birkhaug Stuhr ,&nbsp;Bjørn Steen Skålhegg","doi":"10.1016/j.imlet.2024.106884","DOIUrl":"10.1016/j.imlet.2024.106884","url":null,"abstract":"<div><p>Ablation of the immune-specific catalytic subunit Cβ2 of protein kinase A is associated with a proinflammatory phenotype and increased sensitivity to autoimmunity in mice. Here we show that tumour growth of the adenocarcinoma cell line EO771 in the breast and in the lung after injection into the mammary fat pad and tail vein, respectively, was significantly reduced in mice ablated for Cβ2 compared to wild-type mice. In both cases, the breast and lung tumours showed increased infiltration of immune cells in the mice lacking Cβ2 compared to wild-type mice. Despite this, it appeared that solid tissue- versus intravenously injected EO771 cells evoked different immune responses. This was reflected by significantly increased levels of splenic proinflammatory immune cells and circulating cytokines in Cβ2 ablated mice carrying breast- but not the lung tumours. Moreover, Cβ2 ablated mice injected with EO771 cells showed increased overall survival compared to wild-type mice. Taken together, our results suggest for a role for immune cell-specific Cβ2 in protecting against tumour growth induced by EO771 cells in mice that is reflected in improved overall survival.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106884"},"PeriodicalIF":3.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0165247824000580/pdfft?md5=ed9927c067b97bdfc75f18e01490ff46&pid=1-s2.0-S0165247824000580-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients","authors":"Manuela Capone ,&nbsp;Anna Vanni ,&nbsp;Lorenzo Salvati ,&nbsp;Giulia Lamacchia ,&nbsp;Alessio Mazzoni ,&nbsp;Laura Maggi ,&nbsp;Lorenzo Cosmi ,&nbsp;Francesco Liotta ,&nbsp;Paola Romagnani ,&nbsp;Luigi Cirillo ,&nbsp;Elisa Buti ,&nbsp;Vito Terlizzi ,&nbsp;Chiara Azzari ,&nbsp;Francesco Citera ,&nbsp;Federica Barbati ,&nbsp;Gian Maria Rossolini ,&nbsp;Silvia Bresci ,&nbsp;Beatrice Borchi ,&nbsp;Annalisa Cavallo ,&nbsp;Jessica Mencarini ,&nbsp;Francesco Annunziato","doi":"10.1016/j.imlet.2024.106886","DOIUrl":"10.1016/j.imlet.2024.106886","url":null,"abstract":"<div><h3>Objective</h3><p>Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2 protecting individuals, especially the immunocompromised, from COVID-19. Still, it remains largely unknown how solid organ transplant and different immunosuppressive medications affect development of vaccine-induced immunity.</p></div><div><h3>Methods</h3><p>In this work, we monitored humoral and cellular memory responses after mRNA SARS-CoV-2 two-doses and booster doses vaccination in cystic fibrosis lung transplanted patients (CFT) and compared them with both cystic fibrosis patients without lung transplant (CF) and with kidney transplant recipients (KT). In particular, we investigated the effects of immunosuppressive regimens on immune memory to SARS-CoV-2 after mRNA SARS-CoV-2 vaccine in transplanted patients.</p></div><div><h3>Results</h3><p>Our results showed that immunocompromised transplanted patients displayed a weak cellular and humoral memory to SARS-CoV-2 mRNA vaccination. In addition, obtained data clearly demonstrate that immunosuppressive therapy regimen including antimetabolites, further reduces patients’ ability to respond to vaccination at both humoral and cell-mediated level. Notably, patient treated with antimetabolites showed a lower humoral and cellular response also after a booster dose vaccination.</p></div><div><h3>Conclusion</h3><p>These results, even if obtained on a small patient's cohort, question whether immunocompromised patients need interventions to improve vaccine SARS-CoV-2 mRNA vaccine response such as additional jab or modulation of immunosuppressive therapy.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106886"},"PeriodicalIF":3.3,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential structure and immunomodulatory functions of lipophosphoglycan between Leishmania spp","authors":"Lisa U. Teufel,&nbsp;Leo A.B. Joosten,&nbsp;Jéssica C. dos Santos","doi":"10.1016/j.imlet.2024.106885","DOIUrl":"10.1016/j.imlet.2024.106885","url":null,"abstract":"<div><p>Leishmaniasis is a collective term for several tropical, neglected diseases caused by protozoans of the species <em>Leishmania</em>, 20 of which causing disease in humans ranging from localised self-healing lesions to chronic manifestations which affect the skin or inner organs. Although millions of infections are accounted for annually, treatment options are scarce and limited to medication associated with heavy side-effects and increasing antibiotic resistance. Case studies point towards immunotherapy as effective alternative treatment relying on immunomodulatory properties of e.g., the Bacillus Calmette-Guérin vaccine. <em>Leishmania</em> parasites are also known to modulate the immune system, yet the underlying macromolecules and surface molecules remain widely under characterised. With this short review, we aim to provide a complete summary of the existing literature describing one of the most expressed surface molecule on <em>Leishmania</em> spp, lipophosphoglycan (LPG), which shows great variability between different lifecycle stages and different <em>Leishmania</em> spp. Complete characterisation of LPG may aid to improve treatment and aid the development of vaccination strategies, and open new avenues to exploit the immunomodulatory properties of LPG in unrelated conditions.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106885"},"PeriodicalIF":3.3,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0165247824000592/pdfft?md5=365d7974acaf4c75e767330b92c744f2&pid=1-s2.0-S0165247824000592-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut dysbiosis impacts the immune system and promotes prostate cancer","authors":"Ritis K. Shyanti ,&nbsp;Jazmyn Greggs ,&nbsp;Shalie Malik ,&nbsp;Manoj Mishra","doi":"10.1016/j.imlet.2024.106883","DOIUrl":"10.1016/j.imlet.2024.106883","url":null,"abstract":"<div><p>The gut microbiota is a system of microorganisms in the human gastrointestinal (GI) system, consisting of trillions of microorganisms residing in epithelial surfaces of the body. Gut microbiota are exposed to various external and internal factors and form a unique gut-associated immunity maintained through a balancing act among diverse groups of microorganisms. The role of microbiota in dysbiosis of the gut in aiding prostate cancer development has created an urgency for extending research toward comprehension and preventative measures. The gut microbiota varies among persons based on diet, race, genetic background, and geographic location. Bacteriome, mainly, has been linked to GI complications, metabolism, weight gain, and high blood sugar. Studies have shown that manipulating the microbiome (bacteriome, virome, and mycobiome) through the dietary intake of phytochemicals positively influences physical and emotional health, preventing and delaying diseases caused by microbiota. In this review, we discuss the wealth of knowledge about the GI tract and factors associated with dysbiosis-mediated compromised gut immunity. This review also focuses on the relationship of dysbiosis to prostate cancer, the impact of microbial metabolites short-chain fatty acids (SCFAs) on host health, and the phytochemicals improving health while inhibiting prostate cancer.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106883"},"PeriodicalIF":4.4,"publicationDate":"2024-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The engineered agonistic anti-CD40 antibody potentiates the antitumor effects of β-glucan by resetting TAMs","authors":"Wanpeng Cheng ,&nbsp;Ziyi Huang ,&nbsp;Yongzhe Hao ,&nbsp;Hui Hua ,&nbsp;Bo Zhang ,&nbsp;Xiangyang Li ,&nbsp;Fengqing Fu ,&nbsp;Jing Yang ,&nbsp;Kuiyang Zheng ,&nbsp;Xueguang Zhang ,&nbsp;Chunjian Qi","doi":"10.1016/j.imlet.2024.106882","DOIUrl":"10.1016/j.imlet.2024.106882","url":null,"abstract":"<div><p>Anti-CD40 antibodies (Abs) have been shown to induce antitumor T-cell responses. We reported that the engineered agonistic anti-CD40 Ab (5C11, IgG4 isotype) recognized human CD40 antigen expressed on a human B lymphoblastoid cell line as well as on splenic cells isolated from humanized CD40 mice. Of note, a single high dosage of 5C11 was able to prohibit tumor growth in parallel with an increase in the population of infiltrated CD8⁺ T cells. Furthermore, the antitumor effects of 5C11 were enhanced in the presence of β-glucan along with an increase in the population of infiltrated CD8⁺ T cells. In addition, the numbers of CD86⁺ TAMs and neutrophils were elevated in the combination of 5C11 and β-glucan compared with either 5C11 or β-glucan alone. Furthermore, the abundance of <em>Faecalibaculum</em>, one of the probiotics critical for tumor suppression, was obviously increased in the combination of 5C11 and β-glucan-treated mice. These data reveal a novel mechanism of tumor suppression upon the combination treatment of 5C11 and β-glucan and propose that the combination treatment of agonistic anti-human CD40 antibody 5C11 and β-glucan could be a promising therapeutic strategy for cancer patients.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106882"},"PeriodicalIF":4.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody","authors":"Xue Yao ,&nbsp;Sandro Matosevic","doi":"10.1016/j.imlet.2024.106881","DOIUrl":"10.1016/j.imlet.2024.106881","url":null,"abstract":"<div><p>Wilms’ tumor (WT1), a transcription factor highly expressed in various leukemias and solid tumors, is a highly specific intracellular tumor antigen, requiring presentation through complexation with HLA-restricted peptides.. WT1-derived epitopes are able to assemble with MHC-I and thereby be recognized by T cell receptors (TCR). Identification of new targetable epitopes derived from WT1 on solid tumors is a challenge, but meaningful for the development of therapeutics that could in this way target intracellular oncogenic proteins. In this study, we developed and comprehensively describe methods to validate the formation of the complex of WT1_126–134 and HLA-A2. Subsequently, we developed an antibody fragment able to recognize the extracellular complex on the surface of cancer cells. The single chain variable fragment (scFv) of an established TCR-mimic antibody, specifically recognizing the WT1-derived peptide presented by the HLA-A2 complex, was expressed, purified, and functionally validated using a T2 cell antigen presentation model. Furthermore, we evaluated the potential of the WT1-derived peptide as a targetable extracellular antigen in multiple solid tumor cell lines. Our study describes methodology for the evaluation of WT1-derived peptides as tumor-specific antigen on solid tumors, and may facilitate the selection of potential candidates for future immunotherapy targeting WT1 epitopes.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106881"},"PeriodicalIF":4.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre","authors":"Adèle De Masson ,&nbsp;Ingrid Lazaridou ,&nbsp;Hélène Moins-Teisserenc ,&nbsp;Caroline Ram-Wolff ,&nbsp;Jérôme Giustiniani ,&nbsp;Martine Bagot ,&nbsp;Maxime Battistella ,&nbsp;Armand Bensussan","doi":"10.1016/j.imlet.2024.106871","DOIUrl":"10.1016/j.imlet.2024.106871","url":null,"abstract":"<div><p>Cutaneous T-cell lymphomas (CTCL) are a diverse group of malignant blood disorders characterized by initial skin infiltration, and sometimes, tumor spreading to lymph nodes, blood, and viscera. Mycosis fungoides is the most common form. Sézary syndrome is a distinctive form of CTCL marked by a significant presence of circulating tumor cells in peripheral blood. These diseases are characterized by the plasticity and heterogeneity of the tumor cells in the different tissue compartments, and a difficulty in identifying these tumor cells for diagnostic purposes and therapeutic monitoring. Progress has been made in the understanding of the pathophysiology of these diseases in recent years, and we provide here a review of these advancements.</p></div>","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106871"},"PeriodicalIF":4.4,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Metformin inhibits the pathogenic functions of AChR-specifc B and Th17 cells by targeting miR-146a” [Immunology Letters 250 (2022) 29–40 on Sep 13, 2022/ Manuscript ID: IMLET-D-22-00159R2, PMID: 36108773]","authors":"Yue Hao ,&nbsp;Wei Zhao ,&nbsp;Lulu Chang ,&nbsp;Xingfan Chen ,&nbsp;Chonghui Liu ,&nbsp;Yang Liu ,&nbsp;Lixuan Hou ,&nbsp;Yinchun Su ,&nbsp;Hao Xu ,&nbsp;Yu Guo ,&nbsp;Qixu Sun ,&nbsp;Lili Mu ,&nbsp;Jinghua Wang ,&nbsp;Hulun Li ,&nbsp;Junwei Han ,&nbsp;Qingfei Kong","doi":"10.1016/j.imlet.2024.106866","DOIUrl":"10.1016/j.imlet.2024.106866","url":null,"abstract":"","PeriodicalId":13413,"journal":{"name":"Immunology letters","volume":"268 ","pages":"Article 106866"},"PeriodicalIF":3.3,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0165247824000403/pdfft?md5=69fa9f0fc8c588c5a43291863c901948&pid=1-s2.0-S0165247824000403-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141145174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}